

Genetic Signatures lists on the ASX

Sydney, Australia 1 April 2015: Molecular diagnostics provider Genetic Signatures Ltd (ASX: GSS) has listed on the Australian Securities Exchange (ASX) following the successful closing of its initial public offering (IPO).

Genetic Signatures issued 18.75 million shares at 40 cents to raise \$7.5 million. The Company has 72.9 million shares on issue, giving it a market capitalisation of \$29.1 million at the issue price.

CEO of Genetic Signatures Dr John Melki said: "This is a major step in the evolution of our company. We have been greatly encouraged by the institutional and retail shareholder response to the IPO and the demand for shares. This has allowed us to assemble a high quality register of shareholders. We are excited about transitioning from a private company to a publicly listed company and focussing on delivering our growth objectives."

Proceeds of the IPO will be applied to accelerating the Company's product development pipeline and to increasing new business development via the continued commercial rollout of its products in Australia and the EU as well as entry into the US market.

For further information, visit our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
<p>John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580</p> <p>Robert Birrell Chief Financial Officer rob@geneticsignatures.com T: +61 2 9870 7580</p>	<p>Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231</p>

About Genetic Signatures: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3Base™*. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand.

Molecular diagnostics is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism.

Genetic Signatures' proprietary MDx *3Base™* platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment.

Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis and meningitis.